Long-term data from this registry account for the largest cohort of hypertensive patients who received renal denervation in a real-world clinical setting. This study, recently published by the European Heart Journal, confirms both the safety and efficacy of the procedure with significant and sustained reductions in both office and ambulatory blood pressure. The Global SYMPLICITY…
TCT 2018 | RADIOSOUND-HTN: Testing Different Renal Ablation Techniques and Devices
The clinical efficacy of renal endothelial sympathetic denervation using both radiofrequency and ultrasound endoscopy in the treatment of hypertension has already been proven. This is the first work comparing different techniques and technologies used to this end, which warranted its publication in Circulation. Patients with resistant hypertension were randomized 1:1:1 to: 1) radiofrequency denervation of…
EuroPCR 2018 | RADIANCE-HTN SOLO: Renal Denervation Guided Through Intravascular Ultrasound
Patients eligible for this study suffered from hypertension, had been treated with up to 2 drugs, and presented a daytime ambulatory blood pressure ≥135/85 mmHg and <170/105 mmHg after a 4-week washout period. The study enrolled 146 patients who were randomized 1:1 to denervation treatment or a sham procedure. The reduction in daytime ambulatory systolic blood pressure was greater…
A New Opportunity for Renal Denervation
Courtesy of dr. Carlos Fava. At first, renal denervation enjoyed a considerable boost because, according to early studies, it lowered blood pressure (BP). However, after the results of the SYMPLICITY HTN 3 Trial its popularity decreased. Currently, the development of new technologies and greater operator experience may facilitate a change in this scenario. This…
SPYRAL HTN-OFF MED: Renal Denervation Reloaded?
This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet, seems to give hope to all those that still believe in renal denervation. Interim outcomes suggest that a more intensive denervation of renal arteries, carried out at the SYMPLICITY HTN-3 trial, could reduce blood pressure in patients with untreated mild to moderate hypertension.…
- 1
- 2